Health for Life Capital fund
8
38M
5
0.38
- Stages of investment
- Areas of investment
Summary
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Health for Life Capital fund, startups are often financed by Seventure Partners, Lundbeckfonden Ventures, Innovation Network Corporation of Japan. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Tao Capital Partners, Shinsei Corporate Investment Limited. In the next rounds fund is usually obtained by Tyson Ventures, Taiho Ventures, TMI Investments BV.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Organic Food. Among the various public portfolio startups of the fund, we may underline Axial Biotherapeutics, MycoTechnology, ENTEROME Bioscience The fund has no exact preference in some founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager.
The important activity for fund was in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 0
- Follow on index
- 0.38
- Investments by industry
- Biotechnology (8)
- Biopharma (6)
- Drug Discovery (5)
- Life Science (4)
- Health Care (4) Show 8 more
- Investments by region
-
- France (4)
- United States (3)
- Japan (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Axial Biotherapeutics | 27 Feb 2019 | Biotechnology, Medical, Pharmaceutical, Biopharma | Early Stage Venture | 25M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.